Ovarian Cancer Therapeutics in Major Developed Market Analysis and Research Report 2019: Radiant Insights, Inc
The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission.
The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
7.2.3 High Heterogeneity of the Disease 105<br />
7.2.4 High Cost of Novel Drugs 105<br />
8 Deals 106<br />
8.1 Licens<strong>in</strong>g Deals 106<br />
8.1.1 Clovis Oncology Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Pfizer for PF-01367338 108<br />
8.1.2 PharmaMar Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Janssen for Yondelis 108<br />
8.1.3 Hana Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Tekmira 109<br />
8.1.4 AstraZeneca Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Merck for MK-1775 109<br />
8.1.5 Tesaro Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Merck Sharp & Dohme for <strong>Cancer</strong> Drug<br />
109<br />
8.1.6 Oasmia Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Medison for Paclical 110<br />
8.1.7 Orion Enters <strong>in</strong>to Agreement with Oasmia 110<br />
8.1.8 Ohio University Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Phosplat<strong>in</strong> 110<br />
8.1.9 Genta Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Daiichi Sankyo 110<br />
8.1.10 Celldex Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with the Ludwig Institute for <strong>Cancer</strong><br />
<strong>Research</strong> 110<br />
Browse Full <strong>Report</strong> With TOC @ http://www.radiant<strong>in</strong>sights.com/research/ovariancancer-therapeutics-<strong>in</strong>-major-developed-markets-to-2020-late-stage-pipel<strong>in</strong>efocuses-on-improved-progression-free-surival-<strong>and</strong>-targeted-therapies<br />
8.1.11 NanoCarrier Enters <strong>in</strong>to Licens<strong>in</strong>g Agreement with Kowa for NC-6300 111<br />
8.2 Co-Development Deals 111<br />
8.2.1 Merck Enters <strong>in</strong>to Co-Development Agreement with Endocyte for <strong>Cancer</strong> Drug 112<br />
8.2.2 Pfizer Enters <strong>in</strong>to <strong>Research</strong> Agreement with BC <strong>Cancer</strong> Agency <strong>and</strong> Vancouver<br />
Prostate Centre 113<br />
8.2.3 Almac Discovery Enters <strong>in</strong>to an Agreement with Queen's University Belfast for Drug<br />
Discovery 113<br />
9 Appendix 114<br />
9.1 All Pipel<strong>in</strong>e Drugs by Phase 114<br />
9.1.1 Discovery 114<br />
9.1.2 Precl<strong>in</strong>ical 116<br />
9.1.3 IND/CTA-Filed 122<br />
9.1.4 Phase I 123<br />
9.1.5 Phase II 128<br />
9.1.6 Phase III 133<br />
9.1.7 Pre-Registration 134<br />
9.2 <strong>Market</strong> Forecasts to 2020 134<br />
9.2.1 Global 134
Change language